Sun Pharmaceutical Industries Ltd has secured a critical legal victory in the United States that effectively lifts restrictions on the launch of its drug LEQSELVI (deuruxolitinib), used in the treatment of autoimmune-related hair loss (alopecia areata). The U.S. Court of Appeals for the Federal Circuit vacated a prior injunction imposed by a lower court, freeing Sun Pharma to move forward with its commercialization plans.